source
- Sarepta Therapeutics appoints Michael Severino, former Tessera CEO, as new chief executiveSarepta Therapeutics announced that Michael Severino will become its chief executive, effective Tuesday. Severino previously led Tessera Therapeutics. He replaces Doug Ingram, who said he will ret…
- STAT+: Argenx to buy Forte Biosciences for $2.2BArgenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple autoimmune diseases.